Parkinson’s disease can cause tremor, stiffness and slowed movement that interfere with daily activities. It helps preserve dopamine activity in the brain and may be used alone or alongside levodopa-based treatment.
Azilect contains rasagiline, a selective MAO-B inhibitor used for adults with Parkinson’s disease.
Azilect is used in adults with idiopathic Parkinson’s disease. It may be prescribed as monotherapy during earlier symptoms or as an adjunct to levodopa when motor fluctuations develop.
Rasagiline selectively inhibits MAO-B in the brain. This slows dopamine metabolism, allowing dopamine to remain active for longer in areas involved in movement. The result may be better control of slowness, stiffness and other motor symptoms.
The mechanism differs from levodopa. Levodopa supplies the body with a substance that can be converted into dopamine, while rasagiline reduces dopamine breakdown. These approaches may be used together, although combining dopaminergic medicines can increase unwanted movement or other adverse effects.
Azilect also differs from dopamine agonists. Dopamine agonists stimulate dopamine receptors directly, whereas rasagiline changes dopamine metabolism. The choice depends on symptoms, age, cognitive status, sleep pattern, other medicines and the presence of motor fluctuations.
Clinical guidelines from the National Institute for Health and Care Excellence support the use of MAO-B inhibitors as one option in Parkinson’s disease treatment, with the choice guided by individual symptoms and treatment goals [2]. The benefit is often measured through movement, daily function and periods when medication is working, rather than through a single symptom alone.
Rasagiline has a long-lasting enzyme effect. Missing one tablet does not usually require an extra replacement dose, because taking additional tablets can increase adverse-effect risk.
A treatment break may be needed between Azilect and interacting medicines. The length of that break depends on the medicine involved. Do not start an antidepressant, opioid, cough remedy or herbal product without checking its compatibility with rasagiline.
Antidepressants need careful review. Selective serotonin reuptake inhibitors, serotonin–noradrenaline reuptake inhibitors, tricyclic antidepressants and other centrally acting medicines may require specialist consideration. Severe agitation, high temperature, muscle rigidity or confusion after a medicine change needs urgent medical attention.
The MHRA warns that rasagiline can interact with medicines affecting monoamine, serotonin or opioid pathways [4]. Tell the prescriber about over-the-counter pain medicines, cough products, sleep aids and herbal preparations, not only prescription medicines.
Pregnancy and breastfeeding require specialist assessment because clinical experience with rasagiline in these situations is limited. People with severe hepatic disease should not use it. Those with mild or moderate liver impairment may require a different treatment decision or closer review.
Azilect is not suitable for everyone. It is not for you if any of the following applies:
Rasagiline is commonly tolerated well enough for continued treatment, but adverse effects can occur. Reported reactions include headache, joint pain, indigestion, flu-like symptoms and dizziness. When Azilect is combined with levodopa, dyskinesia, postural hypotension and hallucinations may occur more often than with levodopa alone.
Possible effects include:
A person who feels faint when standing should sit or lie down promptly and report repeated episodes. Low blood pressure can increase fall risk, which is already a major concern in Parkinson’s disease.
Sleepiness deserves direct attention. Some people with Parkinson’s disease develop sudden sleep episodes without much warning, and dopaminergic treatment can add to that tendency. Driving or operating machinery becomes unsafe if drowsiness, poor concentration or sudden sleep occurs.
Hallucinations are not always frightening visual images. They may appear as fleeting shapes, people in a room or shadows at the edge of vision. New hallucinations, confusion or marked behavioural change need prompt clinical assessment.
Serotonin syndrome is rare but serious. Agitation, sweating, fever, shivering, muscle stiffness, diarrhoea and rapid changes in blood pressure can occur when serotonergic medicines are combined inappropriately. The risk depends on the complete medicine list, not on Azilect alone.
Azilect tablets contain rasagiline, a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. MAO-B is an enzyme that breaks down dopamine in the brain. By reducing this breakdown, rasagiline increases the time dopamine remains available for movement control.
Azilect is used in adults with idiopathic Parkinson’s disease. It may be prescribed as monotherapy during earlier symptoms or as an adjunct to levodopa when motor fluctuations develop. The European Medicines Agency (EMA) describes rasagiline as a centrally acting dopaminergic medicine for Parkinson’s disease [1]. The U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), Parkinson’s Foundation and Michael J. Fox Foundation also publish information relevant to Parkinson’s disease treatment.
Parkinson’s disease is linked to progressive loss of dopamine-producing nerve cells. Rasagiline does not restore damaged nerve cells, but it can support the remaining dopamine pathways and improve motor symptom control in suitable patients.
The tablet is taken by mouth. The prescribed amount per intake is selected for the individual patient rather than being one universal dose.
The exact amount per intake is individualised. Azilect is generally taken once daily as an oral tablet, with or without food, according to the prescribed regimen.
Azilect may be prescribed alone or with levodopa. When it is added to levodopa, involuntary movements may become more noticeable, and the levodopa dose may need adjustment by the prescriber. The MHRA product information describes dose-related precautions, interactions and adverse reactions for rasagiline-containing treatment [3].
The medicine is intended for ongoing Parkinson’s disease management, not for occasional relief of a single tremor episode. Its benefit is assessed over time through mobility, stiffness, walking, dexterity and daily activities.
Food does not usually prevent Azilect from being taken, but large amounts of foods rich in tyramine may require caution, especially at higher-than-recommended doses. Examples include heavily matured cheeses, cured meats, fermented products and some alcoholic drinks. The product information gives specific restrictions and interaction warnings, so dietary advice should follow the prescribed regimen rather than internet lists.
Azilect belongs to a different pharmacological group from the main medicines used to manage Parkinson’s disease.
| Treatment approach | Main action | Typical clinical role |
|---|---|---|
| Rasagiline, such as Azilect | Slows dopamine breakdown through MAO-B inhibition | Monotherapy or add-on treatment for motor symptoms |
| Levodopa-based treatment | Provides a dopamine precursor that enters the brain | Strong motor-symptom relief when symptoms affect function |
| Dopamine agonist | Stimulates dopamine receptors | An option for selected adults, with sleep, impulse-control and other risks |
Levodopa often provides the strongest improvement in movement, yet long-term use can be associated with wearing-off periods and dyskinesia. Rasagiline may offer a simpler once-daily approach and can complement levodopa, although its effect may be more modest when symptoms are advanced.
Dopamine agonists can help selected patients, but they may cause excessive sleepiness, hallucinations, swelling or impulse-control problems. Those risks matter when a person drives, works at height, handles machinery or has a history of compulsive behaviours.
Treatment selection is not based on tremor alone. Age, memory, daytime sleepiness, hallucinations, falls, employment demands and other medicines all influence the balance between benefit and tolerability.
Several practical errors can reduce benefit or increase risk:
One patient may notice smoother movement. Another may notice that dressing or writing takes less effort. A useful assessment includes the activities that matter to the person, not only a symptom score.
In clinical practice, Parkinson’s treatment is adjusted around function rather than a laboratory number. A neurologist will usually ask whether walking, dressing, writing, turning in bed or getting out of a chair has changed. The answer helps determine whether Azilect is providing useful benefit.
One common mistake is judging the medicine after one or two tablets. Rasagiline is used as a continuing treatment, and symptom response can be gradual. A prescriber may also need to separate the effect of Azilect from the effect of levodopa or another Parkinson’s medicine.
Doctors also look beyond tremor. Reduced facial expression, smaller handwriting, stiffness, slower movement and shorter steps can matter even when tremor is mild. Balance problems and falls may require a wider treatment plan because changing dopamine treatment alone may not resolve them.
Cognitive symptoms, hallucinations and daytime sleepiness change the risk calculation. An option that helps movement can create difficulty if it increases confusion or causes unsafe sleep episodes. The MHRA and EMA product information both emphasise the need to consider the full clinical picture when using rasagiline [5].
Alcohol may worsen dizziness, impaired coordination, sleepiness and low blood pressure in people taking rasagiline. Parkinson’s disease itself can affect balance, so the combined effect may increase falls or unsafe driving. The EMA product information recommends attention to medicines and substances that can affect the central nervous system; its current product document is dated 2024. Avoid alcohol if it makes you drowsy, unsteady or confused. A pharmacist can review alcohol use alongside the full medicine list.
Stopping Azilect may allow Parkinson’s motor symptoms to return or become more noticeable because the MAO-B inhibition gradually wears off. The medicine should not be stopped casually, especially when it forms part of a wider dopaminergic regimen. NICE guidance on Parkinson’s disease in adults, updated in 2024, supports planned treatment reviews when Parkinson’s medicines are changed. A prescriber should decide whether a taper, a direct stop or another transition is appropriate.
Rasagiline may be associated with sleepiness, dizziness, hallucinations or sudden sleep episodes, especially when used with other dopaminergic medicines. Anyone who develops these symptoms should not drive, cycle in traffic or operate machinery until the problem has been assessed. The MHRA’s 2023 safety information for rasagiline-containing treatment advises attention to impaired alertness and sudden sleep. Concentration should be judged by actual performance, not only by whether the person feels tired.
Pregnancy and breastfeeding require an individual assessment because clinical experience with rasagiline in these situations is limited. The EMA product information for Azilect, issued in 2024, advises caution around pregnancy and states that breastfeeding decisions require consideration of the expected benefit and possible risk. Do not start, stop or restart treatment during pregnancy without a specific plan. The same applies when breastfeeding is being considered.
Azilect is generally taken once daily, and the best time is one that supports consistent use while limiting sleepiness or other unwanted effects. Some people prefer the morning because it fits a regular routine; others may need a different time if daytime drowsiness occurs. The MHRA product information from 2023 allows administration with or without food, subject to the prescribed regimen. Keep the timing stable and report excessive sleepiness, dizziness or changes in movement.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used Azilect alongside my existing Parkinson’s tablets for about six weeks. My morning stiffness seemed easier, and I could type for longer before needing a break. I also noticed more vivid dreams, so my neurologist reviewed the timing of the other tablets.
The first month was not dramatic. I had expected the tremor to disappear, but the useful change was getting through work with less slowing. I became sleepy during the afternoon twice, which meant I stopped driving until the treatment was reviewed.
After several months, walking felt less interrupted and I was more confident turning in narrow spaces. When levodopa was adjusted, I developed extra movements and initially blamed Azilect alone. Recording the timing made the medication review much clearer.
I stopped taking it for several days because I thought it was not doing anything. My stiffness and difficulty getting started became more noticeable. Restarting treatment was discussed with my clinician rather than doubling up, and I now keep the tablets beside my morning water.
